Short answer
CB2 receptors sit on immune cells. Activating them lowers the release of inflammatory cytokines and slows immune cell migration. CB2 counts stay low in the brain regions that drive THC effects, so a CB2 agonist can dampen inflammation without a high. That split makes the receptor a drug target.
cannabinoid receptor agonists and antagonists
The receptor and its gene
The CNR2 gene on chromosome 1p36.11 codes for the CB2 receptor. The protein has 360 amino acids. It is a G protein-coupled receptor and shares about 44 percent of its sequence with CB1. Researchers cloned it in 1993.
how does thc bind to cb1 receptors
CB2 binds the endocannabinoid 2-arachidonoylglycerol (2-AG) with high affinity. Anandamide binds with lower affinity.
Where CB2 receptors are found
- B cells, T cells, natural killer cells, monocytes, and macrophages.
- Microglia, the immune cells of the central nervous system.
- Spleen, thymus, and tonsil tissue, which show high CB2 mRNA counts.
- Osteoclasts and osteoblasts in bone.
- Liver, pancreas, and heart tissue at lower counts.
- Cortex and hippocampus neurons at low counts under normal conditions. Injury raises microglial CB2 counts.
Signaling steps
CB2 couples to Gi/o proteins. Activation inhibits adenylyl cyclase and drops cyclic AMP. The receptor also recruits beta-arrestin2 and activates ERK/MAP kinase pathways. These signals change transcription factor activity, including NF-kB, and cut the output of TNF-alpha, IL-1 beta, and IL-6. Several models show a rise in IL-10.
how does thc bind to cb1 receptors
Downstream effects include less neutrophil recruitment, less mast cell degranulation, and lower nitric oxide and prostaglandin output. Immune cells move less when CB2 is active.
Preclinical evidence
CB2-selective agonists such as HU-308 and JWH-133 produce anti-inflammatory and analgesic effects in rodent models. JWH-133 reduced atherosclerotic lesion size in mice (Steffens et al., 2005). CB2 knockout mice show worse inflammation in several injury models. These agonists do not produce the CB1-driven effects of THC, such as hypothermia and catalepsy, in those models.
Clinical status
No CB2-selective agonist holds FDA approval. Lenabasum, an oral CB2 agonist, reached phase 3 trials for systemic sclerosis and dermatomyositis. The RESOLVE-1 trial in diffuse cutaneous systemic sclerosis reported that lenabasum did not meet its primary endpoint. That result limits claims about clinical anti-inflammatory benefit.
What this means on a label
Total THC and total CBD numbers on a package do not predict CB2 activity. THC is a weak partial agonist at CB2. CBD binds CB2 with low affinity and acts as a negative allosteric modulator at high concentrations. Beta-caryophyllene, a terpene in black pepper, hops, and cannabis, binds CB2 and appears in some products. Reported binding values differ by assay, and human trial data for CB2 agonists in inflammation remain thin.
Open questions
Researchers do not know the dose of a CB2 agonist that lowers inflammation in humans without tolerance or immune suppression. Tissue distribution, biased signaling at beta-arrestin, and receptor upregulation during inflammation all change the response. Product availability and convenience say nothing about CB2 engagement.